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Highlights 
 
 The mean age at diagnosis of Duchenne Muscular Dystrophy is around 4.2 -5 years all over 
the world. 
 A delayed diagnosis of DMD has several clinical and therapeutic implication 
 The mean age at diagnosis of DMD in Italy in the last decade was around 3.5 years. 
 All male children should be screened in early infancy for DMD to avoid a delay in diagnosis 
 
 
ABSTRACT 
 
Despite all the advances in diagnosis and management of Duchenne muscular dystrophy over the  
past 50 years, the average age at diagnosis at most countries in the world around is still around 4-5 
years. This retrospective study investigate the age at diagnosis in Italy in the past 10 years.  We  
report findings from 384 boys who were diagnosed with DMD from 2005 to 2014. The mean age at 
first medical contact, which raised the suspicion of DMD, was 31 months. The mean age  at 
diagnosis was 41 months. The finding that more frequently brought to suspect a DMD was the 
incidental finding of consistent elevated creatine kinase serum level detected during routine 
assessments in children undergoing general anesthesia or with intercurrent illness. This  was  
followed by motor delay and signs of muscle weakness. Initial concerns were raised by general 
pediatricians (29%), specialists at tertiary centers (35%) or first level hospitals (23%). In children 
presenting incidental elevated creatine kinase values the diagnosis was achieved earlier than in 
children presenting a developmental delay. The mean age at diagnosis in our cohort was about 10-   
12 months lower than that reported in other countries. 
 
 
INTRODUCTION 
 
Duchenne muscular dystrophy (DMD) is the most common muscular dystrophy of childhood and 
affects approximately one in every 5,000 male newborns [1]. 
The onset of muscle weakness is typically in early childhood. Boys generally lose the ability to 
walk before the age of 13 years and death occurs in late teens or early 20s due to respiratory or 
cardiac failure [2]. Non-progressive cognitive dysfunction can also be present [3]. 
Page 4 of 12 
 
 
 
 
 
 
 
4 
 
The mean age at diagnosis of DMD has been reported to be around the age of 4.2-5 years in several 
countries with a delay of about 2 years between the first symptoms are noted, and the diagnosis [4- 
10]. In order to evaluate the age at diagnosis of DMD in Italy and to compare our results to other 
studies performed in other countries [4-9], we retrospectively explored the age of DMD diagnosis, 
performed in the 15 tertiary Centers for muscular dystrophies in Italy, in the past 10 years. The aims 
of this study were to define the age at diagnosis of DMD in Italy, the most frequent signs that raised 
the suspicion of DMD and to assess the diagnostic pathway to reach the diagnosis, in Italy, 
highlighting its strengths and weaknesses. 
 
 
Methods 
 
This study includes 15 tertiary Italian Neuromuscular Center involved in the diagnosis and follow- 
up of DMD boys. The study was approved by the Ethic Committee of the coordinator center 
(Bambino Gesù Hospital). 
Clinical charts of the children, who received a diagnosis of DMD from January 2005 to December 
2014, were reviewed by a clinician in each center. 
A dedicated excel file for data collection was provided by the coordinator (A.D.) and used in all 
centers after a training session. 
For each boy the following information were collected:  region of origin of patient, family history  
of DMD, age at first medical concerns, person who suspected the diagnosis, presenting sign or 
symptom, age at diagnosis, interval between the first suspicion of DMD and diagnosis, type of 
investigation that was performed to reach the diagnosis. (biopsy and/or genetic test). We considered 
as presenting sign or symptom the first sign or symptom revealed by a physician that raised the 
suspect of DMD. Only one sign or symptom, among the following, could be filled into our survey 
and was considered as the predominant sign: incidental finding of elevated creatine kinase 
(hyperCKemia) or transaminases serum levels, motor delay (a delay of motor milestones without 
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evidences of muscle weakness), tip-toe walking, muscle weakness, intellectual disability and speech 
delay. We considered as the age at diagnosis either the date of the muscle biopsy or the genetic test. 
All patients missing some information were excluded from the study. 
A general descriptive statistics was generated to analyze the data. 
The familial cases were analyzed separately. 
 
 
RESULTS 
 
Nine of the 15 tertiary centers involved in this study were in the northern part of Italy, 4 in the 
center and 2 in the south. 
We identified 384 Italian boys diagnosed with DMD in the last 10-years. The patients, classified 
according to their region of origin, were equally distributed from North (n= 134), Center (n= 115) 
and South (n= 135) of Italy. Thirty boys (7,8%) had a positive family history of DMD. Forty-two 
patients were excluded by the study because not all the appropriate information were available. 
The mean age at first medical contact, which raised the suspicion of DMD, was 31 months (range 0- 
95 months). The mean age at diagnosis was 41 months (range 0.3- 135 months). The reasons that  
led the child to medical attention were: incidental finding of consistent hyperCKemia (n=170, 44,3 
%), motor delay (n=61, 15.9%), muscle weakness (n=54, 14,0%), increased levels of transaminases 
in serum (n=36, 9%), family history (n=30; 7,8%), tip-toe walking (n=20, 5,2%), intellectual 
disability (n=10, 2.6 %), speech delay, (n=4, 1%), other symptoms ( 0.4%). 
In the group of children who presented hyperCKemia as an incidental finding, the mean age at 
suspicion was 25 months. In the two groups of patients with intellectual disability and motor delay, 
the first suspect of DMD was formulated at the mean age of 30 months, whereas in patients 
showing tip-toe walking or muscle weakness DMD was suspected later (45 and 49 months 
respectively) (see figure 1). 
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Initial concerns of DMD were more often raised by specialist at first level hospital (35%), followed 
by general pediatricians (29%) and specialists at tertiary level hospitals (23 %). In the remaining 
13% initial concerns was raised by parents. 
Following a clinical suspect, the CK level was tested in all patients. In the whole cohort, EMG was 
performed in 34patients (9%), and muscle ultrasound in 5 (1,3%). 
Only a small percentage (18%) underwent further clinical and instrumental investigations before 
prompting a test for DMD. Seventeen out of the 36 patients (9.3%) who were initially examined for 
incidental high transaminases serum level, underwent liver ultrasound and serologic tests for 
hepatitis and in two cases a liver biopsy was performed. Ten of the 61 patients (2,6% ) with ‘pure’ 
motor delay as the presenting symptom, underwent orthopedic or physiatrist examination before the 
CK assessment. Four of the 10 patients with intellectual disability had brain MRI and 
electroencephalography. 
The mean interval between the first suspicion and the diagnosis of DMD was 12 months (range 10 
days to 80 months). The interval was shorter in patients with the incidental finding of consistent 
hyperCKemia and longer in the group of patients with intellectual disability and tip-toe walking 
(see table 1). 
In 275 of the 384 boys (%) muscle biopsy confirmed absence or near absence of dystrophin in the 
muscle. In 215 boys (55%) muscle biopsy was performed before the genetic test, whereas in 60 
boys it was performed after a negative genetic test for deletions or duplications (n=29) or to better 
define the phenotype (n=31). The diagnosis of DMD was genetically confirmed in all but two cases 
and in 109 cases it preceded the muscle biopsy. The percentage of patients who underwent a 
diagnostic muscle biopsy decreased over the years, passing from 69%, in the period 2005-2009, to 
44 %, in the quinquennial  2009-2014. 
No significant differences in the diagnostic pathway and age at diagnosis in the three different areas 
of Italy were found. The mean age of clinical suspect was shorter in the North of Italy (6 months 
less than in the South), while the time for diagnosis was longer (5 months more than in the South). 
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The mean age at diagnosis of familial cases was 33 months (ranging between 10 day to 98 months). 
 
 
 
Discussion 
 
Despite advances in technology and increased availability of genetic testing, diagnosis in DMD is 
still often delayed, even when the first signs or symptoms are recognized early. Audit data and 
published papers, from different countries, show that the mean age at the diagnosis is still averaging 
between 4.2 and 5 years and is almost identical from the reports in the early 1980s[4-10]. 
In this study, we reviewed the mean age at diagnosis of a large cohort of Italian DMD patients, that 
were referred to tertiary care centers over the past 10 years and we analyzed different factors 
leading to the final diagnosis. Undoubtedly, we were not able to identify and include all DMD 
patients diagnosed in Italy in the last decade, thus this work is not intended as an epidemiological 
study on the incidence of DMD in Italy but rather it would describe the diagnostic approach to the 
disease. Over the last decade in Italy the mean age at diagnosis, was 41 months (3.5 ys), about 10- 
12 months less than the age reported in other studies [4-10]. The most frequent finding that brought 
to suspect DMD was the incidental finding of elevated CK or of transaminases serum levels (53% 
of cases). This was followed by delay in motor milestones (16% of cases). Unexpectedly, at 
variance with other studies, intellectual disability or speech delay were the first sign in only 3.6 % 
of cases. 
The difference between our findings and previously published data is probably related to the fact 
that in Italy blood tests, including transaminases, and often CK, are often routinely requested by 
general pediatricians in children with vomiting, diarrhea or prolonged fever and, when needed, 
before general anesthesia. Once the elevated CK level is detected, the boys are often referred 
directly to a tertiary care center and this probably explains the shorter duration to reach the 
diagnosis in these cases. 
Even when the presenting sign was different, such as delayed milestones, CK levels were the first 
and often the only investigation performed by physicians, including general pediatricians, and this 
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promptly led to the appropriate investigation for DMD. These data are different from other 
countries where the CK test was almost always performed in secondary care and the time to obtain 
the result significantly contributed to the diagnostic delay [5,9].The earlier age at diagnosis in Italy, 
confirm that, as reported by other authors [5], assessing CK levels in primary care can reduce the 
time of diagnosis. 
Some aspects of neurodevelopmental delay in the first years, including intellectual disability and 
speech difficulties were the presenting symptoms in about 20% of patients, confirming the 
suggestion of other authors that CK levels should be tested in young children with walking delay 
(>18 months) [5],delayed speech or global developmental delay [5,10]. It is of interest that in our 
cohort the most delayed diagnosis (up to 135 months) occurred in patients not manifesting global 
developmental delay but having signs of muscle weakness, such as difficulties in running or in 
getting up from the floor, or showing tip-toe walking (14 and 5,2%, respectively) as these were 
probably thought to be  a mild motor delay or clumsiness that would improve with age. 
Another interesting finding in our study was that the mean age at diagnosis of a familial case was 
lower than in the sporadic cases but was still at31 months (versus 41 months in sporadic cases).  
This was not systematically assessed but it is probably due to the fact that if the children were close 
in age, by the time the first child had a diagnosis, the second was already older than 2 years. 
Another interpretation of this finding could reflect the choice of the family not to receive an early 
diagnosis in their second younger son. 
In the diagnostic pathway in Italy we found that muscle biopsy is still performed -before the genetic 
test- in 55 % of cases, in contrast with the recent International Guidelines [10] that recommend to 
perform muscle biopsy only in cases of negative MLPA test for deletion/duplication. However, as 
shown in the results, this approach has progressively changed over the years because of the 
increasing availability of the MLPA test in tertiary neuromuscular centers. 
One of the strengths of our survey is that it includes all the tertiary care centers in Italy and 
therefore provides an overall picture of all the patients who are followed by specialists.  This  is 
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however also a possible limitation as the large number of centers potentially increase the possibility 
that data may have interpreted differently by the different investigators. In order to reduce this bias, 
we had a preliminary survey and, after reviewing the first results, we had a training session 
discussing inconsistencies and agreeing on how to code different signs and symptoms. 
Our results confirm that CK levels could be an accurate method to suspect DMD and contribute to 
the ongoing discussion supporting early screening in DMD. Keeping in mind the risk of recurrence 
in a family we believe that a CK test screening should be performed in early infancy. We recognize 
the practical challenges to make this screening feasible. However, we believe that it would be 
proposed and discussed with the family concurrently to routine obligatory vaccinations planned at 
the age of 1 year. 
Early diagnosis would not only allow a prompt genetic counseling to identify carriers and to offer 
prenatal diagnosis, reducing the number of affected siblings [8,9] but also allow to start early 
intervention. This would include intervention for early neurodevelopmental  difficulties  that  are 
often present in very young boys [12,13],as well as the use of nighttime splints that are often needed 
to prevent the development of  severe ankle contractures [2] and steroid treatment [14,15].Their use 
is recommended by the ‘plateau phase’ of the disease (between the ages of 4 and 6 years) but recent 
advances suggest that, early treatment might be associated with slower functional decline and a  
better long term outcomes [14,15]. Early diagnosis will become even more important as several 
therapeutical approaches are currently being investigated in phase III clinical  trials  and,  should 
these become available [16,17], ought be started as early as possible before muscle tissues lose the 
ability to self-regenerate [18] . 
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Figure 1: in the graph are reported the mean ages at which the suspicion of a DMD was reached, in 
relation to the presenting symptom. 
 
 
Table 1: in table are summarized the data analysis of ages at suspicion and diagnosis and the 
 
interval between presenting symptoms and diagnosis in the different groups of patients. 
 
 
 
 
Regions of origin Age at first suspect Age at diagnosis Time for diagnosis 
Norther n=134 
Central n=115 
Souther n=135 
30 mo (0.2-84) 
 
32 mo (2-86) 
 
36 mo (0.2-92) 
42 mo (1.1-101) 
 
39 mo (2-102) 
 
45 mo (0.3-135) 
12 mo 
 
7 mo 
 
9 mo 
Presenting sign or 
symptom 
   
Whole cohort 31 mo (0.2-95 mo) 41 mo (0.3-135 mo) 10 mo 
High CK/transaminases 25 mo (0-60 mo) 28.7 mo (1-81 mo) 3.7 mo 
Motor delay 30 mo (10-84 mo) 48 mo (11-107 mo) 18 mo 
Intellectual disability 30 mo (12-72 mo) 52 mo (13-102 mo) 22 mo 
Muscle weakness 45 mo (18-92 mo) 62 mo (25-103 mo) 17 mo 
Tip-toe walking 49 mo (12-95 mo) 70 mo (26-135 mo) 21 mo 
Family history 27 mo (0-52 mo) 33 mo (1-69 mo) 6 mo 
 
